Full-Time

Associate Director / Director

Clinical Pharmacology

Iambic Therapeutics

Iambic Therapeutics

51-200 employees

AI-driven discovery for oncology and neurology

Compensation Overview

$164k - $245k/yr

+ 401(k) matching

Remote in USA + 1 more

More locations: San Diego, CA, USA

Hybrid

The role may be performed remotely within the United States or from the San Diego office.

PhD

Category
Biology & Biotech (1)
Required Skills
R
Pharmacology

Get referred to Iambic Therapeutics

See people who can refer or advise you

Requirements
  • A PhD or equivalent in Pharmacology, Biomedicine, Biochemistry, or a related scientific discipline.
  • A minimum of 5 years of relevant experience within the pharmaceutical industry, contract research, or clinical research.
  • Experience with the clinical development of oncology small-molecule therapeutics, including familiarity with dose-escalation/expansion trial designs and combination-therapy regimens.
  • Proficiency using Phoenix WinNonlin for non-compartmental analysis.
  • Working knowledge of physiologically based pharmacokinetic modeling and current drug-drug interaction regulatory frameworks, including ICH M12 and FDA guidance.
  • Hands-on clinical pharmacology experience writing regulatory and scientific documentation, including Clinical Study Protocols, Standard Operating Procedures, Statistical Analysis Plans, Clinical Study Reports, and other regulatory documents.
  • Familiarity with pharmacokinetic bioanalytical methods development and validation.
  • Ability to manage multiple projects, prioritize work effectively to meet deadlines, anticipate potential problems within project plans, and communicate alternatives effectively.
  • Ability to communicate and work collaboratively as a member of a cross-functional team.
Responsibilities
  • Represent the Clinical Pharmacology line function and work on multidisciplinary oncology small-molecule program teams spanning clinical, DMPK, regulatory, biometrics, CMC, and related functions.
  • Independently analyze, interpret, and report clinical pharmacokinetic, PK/PD, and exposure-response data for oncology small-molecule assets as a member of multidisciplinary development program teams.
  • Partner with Clinical Development to design clinical pharmacology components of oncology studies, including first-in-human dose-escalation/expansion, drug-drug interaction, hepatic and renal impairment, food-effect, and cardiac safety ECG/QT studies, as well as combination-therapy dosing strategies.
  • Apply quantitative approaches, including PBPK, population PK, and exposure-response modeling, to inform dose selection and drug-drug interaction risk assessment.
  • Write and review Clinical Study Protocols, Investigator's Brochures, Standard Operating Procedures, Statistical Analysis Plans, Clinical Study Reports, and other regulatory and scientific documentation.
  • Maintain working knowledge of pharmacology, biology, therapeutics, drug metabolism, bioanalysis, and biopharmaceutics.
  • Review and author scientific publications, abstracts, and posters.
  • Mentor junior scientists within the Clinical Pharmacology function.
Desired Qualifications
  • Experience with the clinical development of oncology small-molecule therapeutics, including familiarity with dose-escalation/expansion trial designs and combination-therapy regimens.
  • Working knowledge of physiologically based pharmacokinetic modeling and current drug-drug interaction regulatory frameworks, including ICH M12 and FDA guidance.
  • Familiarity with pharmacokinetic bioanalytical methods development and validation.

Iambic Therapeutics develops therapeutics using an AI-driven discovery platform, focusing on oncology and neurological diseases in clinical-stage programs. The platform combines advanced AI models with automated experiments to predict molecular properties faster and with less data, speeding identification and optimization of drug candidates. It differentiates itself by maintaining an in-house pipeline alongside strategic pharmaceutical partnerships to advance programs and earn milestones and royalties. The goal is to bring new therapies to patients by accelerating discovery and development through AI and automation.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$303M

Headquarters

San Diego, California

Founded

2019

Get referred to Iambic Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda’s February 2026 deal provides upfront, research, and technology-access payments.
  • Bayer joined June 2026, expanding non-dilutive validation beyond oncology into broader drug discovery.
  • Iambic raised over $100 million in November 2025, supporting runway into 2028.

What critics are saying

  • Takeda’s billion-dollar value depends on milestones; failure in programs kills economics.
  • IAM1363 remains single-asset clinical proof; Phase 1b setbacks would crush credibility.
  • Big pharma can internalize AI discovery, and Bayer or Takeda can switch vendors.

What makes Iambic Therapeutics unique

  • NeuralPLexer and Enchant anchor Iambic’s AI stack for structure and endpoint prediction.
  • Takeda chose Iambic in February 2026, validating platform value with blue-chip pharma.
  • IAM1363 reached Phase 1/1b in two years, versus six-year industry averages.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Company Match

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
Intelligence360 News
Dec 3rd, 2025
Iambic Therapeutics raises $125M in new funding

Iambic Therapeutics has filed a notice with the US Securities and Exchange Commission for an exempt offering to raise $125 million in new funding. The filing was made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act, which allows companies to sell securities without registration under the Securities Act of 1933. Federal securities law requires such notices to be filed within 15 days after the first sale of securities in the offering. No additional details about the funding round, including investors or valuation, were disclosed in the filing.

Iambic Therapeutics
Nov 11th, 2025
Iambic Raises Over $100 Million in an Oversubscribed Round to Advance its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies

San Diego, CA – Nov. 10, 2025 – Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced raising over $100 million in an oversubscribed financing round with balanced support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar Investment Authority, Regeneron Ventures, Sequoia, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati, and others.

Endpoints News
Nov 10th, 2025
Iambic Therapeutics raises $100M funding

Iambic Therapeutics has secured over $100 million in a new funding round, as revealed by CEO Tom Miller. The investment comes from ARK and Regeneron, highlighting significant financial backing for the San Diego-based biotech company.

EntArabi
Jun 20th, 2024
Iambic Therapeutics raises $50M in Series B

Iambic Therapeutics, a US-based biotech company, raised $50 million in an expanded Series B funding round led by Mubadala Capital. The round included Qatar Investment Authority, Exor Ventures, and existing investors like Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, and Tao Capital Partners. This funding is part of a previous $100 million Series B round closed in October 2023. The funds will be used to advance Iambic's clinical and preclinical programs.

Pharmaceutical Business Review
Jun 19th, 2024
Iambic secures $50m to bolster clinical oncology programme pipeline

Iambic Therapeutics has secured $50m in its Series B extension financing round to bolster its pipeline comprising clinical oncology programmes.